X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, the company will utilize OT-101 (trabedersen), currently under investigation in mid-stage clinical trials with adult patients, for treating brain cancer and diffuse intrinsic pontine glioma.
Lead Product(s): Trabedersen
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Oncotelic Therapeutics
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 29, 2024
Details:
MIE-101, a Cowpea mosaic virus has shown to engage multiple Toll-like receptors on host immune cells in the tumor that have evolved to detect foreign invaders enhanced antitumor effects when combined with immune checkpoint inhibitors and other standard cancer therapies.
Lead Product(s): MIE-101
Therapeutic Area: Oncology Product Name: MIE-101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2021
Details:
Under the agreement, Mosaic has licensed rights to develop and commercialize new treatment candidates including lead product, MIE-101, is derived from the cowpea mosaic virus (CPMV), that broaden the scope and capabilities of the protein nanoparticle platform to treat cancer.
Lead Product(s): MIE-101
Therapeutic Area: Oncology Product Name: MIE-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: University of California San Diego
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 06, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
